secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0000950170-24-046459
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024
-------------------------------------------------------------------------------

- ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.
- Preclinical data selected for oral presentation at ASGCT on May 10, 2024 in Baltimore.
- ADI-270 uses CD27-based targeting and armored design to counteract tumor microenvironment and host T-cell clearance.
- Company confirms IND submission for renal cell carcinoma remains on track for Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/0000950170-24-046459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/acet-20240422.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-046459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer